{"id":"W4410811633","doi":"10.1200/jco.2025.43.16_suppl.11120","title":"Final patient-reported outcomes (PROs) in unselected men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as initial treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from the phase 3 TALAPRO-2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Internal medicine; Oncology; Cancer; Androgen receptor; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002332772,0.0006183776,0.0007741414,0.0005227515,0.0002483106,0.0005738001,0.0004259082,0.0004685754,0.001693111],"category_scores_gemma":[0.002204891,0.0002271395,0.001677611,0.0007433734,0.0002487537,0.0005527496,0.0004838555,0.0008494739,0.0003128651],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003413844,"about_ca_system_score_gemma":0.0002836107,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001092553,"about_ca_topic_score_gemma":0.001909867,"domain_scores_codex":[0.9991653,0.0004060846,0.00007470922,0.0001254049,0.0001423614,0.00008620754],"domain_scores_gemma":[0.9979652,0.0004486617,0.001030512,0.00009929695,0.000172081,0.0002843027],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2258348,0.002795749,0.6855475,0.001061686,0.009169526,0.0002257058,0.0003251022,0.003408197,0.002389727,0.0001433468,0.004893575,0.06420506],"study_design_scores_gemma":[0.008150974,0.03083559,0.9536515,0.00006011931,0.002759049,0.0002988946,0.0001157977,0.001354593,0.0007876708,0.0001028773,0.001838836,0.00004400781],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910273,0.001790312,0.0002317359,0.00008683452,0.00002635094,0.0001744588,0.005550548,0.00002277105,0.001089735],"genre_scores_gemma":[0.990533,0.0004338029,0.00026931,0.0001084209,0.00003940394,0.000229986,0.007853089,0.000005720064,0.0005272355],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002332772,"threshold_uncertainty_score":0.01233703,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1912337840206246,"score_gpt":0.5290824125384349,"score_spread":0.3378486285178103,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}